Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis

被引:44
作者
Liu, Huang-Jun [1 ,2 ,3 ]
Liao, Hai-Han [1 ,2 ,3 ]
Yang, Zheng [1 ,2 ,3 ]
Tang, Qi-Zhu [1 ,2 ,3 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan 430060, Peoples R China
[2] Wuhan Univ, Cardiovasc Res Inst, Wuhan 430060, Peoples R China
[3] Hubei Key Lab Cardiol, Wuhan 430060, Peoples R China
基金
中国国家自然科学基金;
关键词
ATRIAL-FIBRILLATION PROMOTION; LEFT-VENTRICULAR HYPERTROPHY; PPAR-GAMMA; MYOCARDIAL FIBROSIS; HEART-FAILURE; DIABETIC CARDIOMYOPATHY; CARDIOVASCULAR-DISEASE; NATRIURETIC PEPTIDE; TYPE-1; RECEPTOR; DOWN-REGULATION;
D O I
10.1155/2016/2198645
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily, which plays a central role in regulating lipid and glucose metabolism. However, accumulating evidence demonstrates that PPAR gamma agonists have potential to reduce inflammation, influence the balance of immune cells, suppress oxidative stress, and improve endothelial function, which are all involved in the cellular and molecular mechanisms of cardiac fibrosis. Thus, in this review we discuss the role of PPAR gamma in various cardiovascular conditions associated with cardiac fibrosis, including diabetes mellitus, hypertension, myocardial infarction, heart failure, ischemia/reperfusion injury, atrial fibrillation, and several other cardiovascular disease (CVD) conditions, and summarize the developmental status of PPAR gamma agonists for the clinical management of CVD.
引用
收藏
页数:12
相关论文
共 106 条
[91]   Ameliorative Role of Rosiglitazone in Hyperhomocysteinemia-Induced Experimental Cardiac Hypertrophy [J].
Singh, Amrit Pal ;
Kaur, Tajpreet ;
Dahiya, Randhir Singh ;
Singh, Nirmal ;
Bedi, Preet Mohinder Singh .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 56 (01) :53-59
[92]   Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice [J].
Tao, Lichan ;
Shen, Sutong ;
Fu, Siyi ;
Fang, Hongyi ;
Wang, Xiuzhi ;
Das, Saumya ;
Sluijter, Joost P. G. ;
Rosenzweig, Anthony ;
Zhou, Yonglan ;
Kong, Xiangqing ;
Xiao, Junjie ;
Li, Xinli .
SCIENTIFIC REPORTS, 2015, 5
[93]   Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring [J].
Torres, Thiago da Silva ;
Aguila, Marcia Barbosa ;
Mandarim-de-Lacerda, Carlos Alberto .
PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (09) :642-646
[94]   Peroxisome proliferator-activated receptors for hypertension [J].
Usuda, Daisuke ;
Kanda, Tsugiyasu .
WORLD JOURNAL OF CARDIOLOGY, 2014, 6 (08) :744-754
[95]   Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2 [J].
Wang, Hao ;
Zhu, Qiwei ;
Ye, Ping ;
Li, Zongbin ;
Li, Yang ;
Cao, Zeling ;
Shen, Lin .
BIOSCIENCE TRENDS, 2012, 6 (06) :325-332
[96]   Pharmacogenomic, Physiological, and Biochemical Investigations on Safety and Efficacy Biomarkers Associated with the Peroxisome Proliferator-Activated Receptor-γ Activator Rosiglitazone in Rodents: A Translational Medicine Investigation [J].
Wang, Xinkang ;
Liu, Xiaorong ;
Zhan, Yutian ;
LaVallie, Edward R. ;
DiBlasio-Smith, Liz ;
Collins-Racie, Lisa ;
Mounts, William M. ;
Rutkowski, J. Lynn ;
Xu, Xin ;
Goltsman, Ilia ;
Abassi, Zaid ;
Winaver, Joseph ;
Feuerstein, Giora Z. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (03) :820-829
[97]   PPAR agonists for the treatment of cardiovascular disease in patients with diabetes [J].
Wilding, J. P. H. .
DIABETES OBESITY & METABOLISM, 2012, 14 (11) :973-982
[98]   PPAR Gamma Expression Levels during Development of Heart Failure in Patients with Coronary Artery Disease after Coronary Artery Bypass-Grafting [J].
Wojtkowska, Izabela ;
Tysarowski, Andrzej ;
Seliga, Katarzyna ;
Siedlecki, Janusz A. ;
Juraszynski, Zbigniew ;
Marona, Milosz ;
Greszata, Lidia ;
Skrobisz, Anna ;
Kaminski, Karol ;
Sawicki, Robert ;
Stepinska, Janina .
PPAR RESEARCH, 2014, 2014
[99]   Cellular and molecular mechanisms of fibrosis [J].
Wynn, T. A. .
JOURNAL OF PATHOLOGY, 2008, 214 (02) :199-210
[100]   L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression [J].
Zambrano, Sonia ;
Blanca, Antonio J. ;
Ruiz-Armenta, Maria V. ;
Miguel-Carrasco, Jose L. ;
Arevalo, Miguel ;
Vazquez, Maria J. ;
Mate, Alfonso ;
Vazquez, Carmen M. .
BIOCHEMICAL PHARMACOLOGY, 2013, 85 (07) :937-944